Based on the ALIGOS THERAPEUT. DL-01 stock forecast from 0 analysts, the average analyst target price for ALIGOS THERAPEUT. DL-01 is not available over the next 12 months. ALIGOS THERAPEUT. DL-01’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ALIGOS THERAPEUT. DL-01 is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, ALIGOS THERAPEUT. DL-01’s stock price was EUR 0.429. ALIGOS THERAPEUT. DL-01’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -39.15% over the last year.
No recent analyst target price found for ALIGOS THERAPEUT. DL-01
No recent average analyst rating found for ALIGOS THERAPEUT. DL-01
Company Overview ALIGOS THERAPEUT. DL-01
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Read Less
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical tri...Read More
Frequently Asked Questions About ALIGOS THERAPEUT. DL-01 (5WK:F) Stock
Stock Target Advisor's fundamental analysis for ALIGOS THERAPEUT. DL-01's stock is Slightly Bearish.
Unfortunately we do not have enough data on 5WK:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 5WK:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 5WK:F's stock to indicate if its overvalued.
The last closing price of 5WK:F's stock was EUR 0.43.
The most recent market capitalization for 5WK:F is EUR 1.65M.
Unfortunately we do not have enough analyst data on 5WK:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ALIGOS THERAPEUT. DL-01's stock.
As per our most recent records ALIGOS THERAPEUT. DL-01 has 68 Employees.
ALIGOS THERAPEUT. DL-01's registered address is One Corporate Drive, South San Francisco, CA, United States, 94080.
You can get more information about it from ALIGOS THERAPEUT. DL-01's website at https://www.aligos.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About ALIGOS THERAPEUT. DL-01 (5WK:F) Stock
Stock Target Advisor's fundamental analysis for ALIGOS THERAPEUT. DL-01's stock is Slightly Bearish.
Unfortunately we do not have enough data on 5WK:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 5WK:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 5WK:F's stock to indicate if its overvalued.
The last closing price of 5WK:F's stock was EUR 0.43.
The most recent market capitalization for 5WK:F is EUR 1.65M.
Unfortunately we do not have enough analyst data on 5WK:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ALIGOS THERAPEUT. DL-01's stock.
As per our most recent records ALIGOS THERAPEUT. DL-01 has 68 Employees.
ALIGOS THERAPEUT. DL-01's registered address is One Corporate Drive, South San Francisco, CA, United States, 94080.
You can get more information about it from ALIGOS THERAPEUT. DL-01's website at https://www.aligos.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 5WK:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Join over half-million smart investors across the world
Loading...
The Adjusted Closing and Unadjusted Closing sections display stock prices with and without adjustments, respectively. The Share Trading Volume section shows the stocks trading volume over time, indicating market activity. The Compare Performance section allows you to analyze a stocks performance against others by entering symbols and clicking Add to see relative returns. These tools aid in making informed investment decisions. Use the date range selectors to view trends from the past month (1m), three months (3m), six months (6m), year-to-date (YTD), one year (1y), five years (5y), or all available data (All).
